A short sqeeze in Harvard Scientific (HVSF).
Ha, Ha. Here's the chance all small-cap longs have waited for.
Rumor (:-)) has it that there has been major short selling (up to 1mm shares) in HVSF
by folks who thought they had stock available as a result of an upcoming note
conversion with the company. Problem seems to be the time for conversion is (NOT)
40 days as assumed, but the note is convertable in 1 yr. Appears they may have sold
stock they don't have. Anyway, that's all rumor. P.S. read the news releases from
company and look at the recent volume on way down.
Anyway, the stock was recently recommended by Kostek- story to follow. If you see
stock starting up, the sqeeze will be on. That's a lot of shares to cover with very little
stock available. Price could easly move into the $4 range in very short period.
Medium term, company has THE best pecker hardner medicine (period) on market
and expects to put major pressure on Upjohn's market leading injection (needle in the
dick) approach. UpJohn has done all its scientific DD on HVSF's patented technology,
and one could resonably speculate that Upjohn would elect to buy out company at
some price north of $10-12/s within next six to eight months. In Feb, independent
biotech advisory svc. had a projection of $26-28 within 24 months as technology
completed testing and company sales and market share increased. As HVSF
completes its Phase II & III testing, the price will keep keep going up. This is a neat
story and immediate play for the intrepid.
Report to follow on next message.
Good luck.
Gm |
